XERIS BIOPHARMA HOLDINGS INC (XERS)
US98422E1038 - Common Stock
| MRQ (2024-3-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | 2020 (2020-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash Equivalents | 62.69M | 67.45M | 122.00M | 67.30M | 37.60M | |||
| Marketable Securities | 24.66M | 5.00M | 0.00 | 35.20M | 96.20M | |||
| Receivables | 37.41M | 39.20M | 30.80M | 17.50M | 6.90M | |||
| Inventories | 40.88M | 38.84M | 24.70M | 18.10M | 8.40M | |||
| Other Current Assets | 7.64M | 5.78M | 9.30M | 4.60M | 3.20M | |||
| Total Current Assets | 173.28M | 156.26M | 186.80M | 142.60M | 152.20M | |||
| Non-Current Assets | ||||||||
| PPE Net | 28.81M | 29.18M | 9.50M | 6.60M | 6.70M | |||
| Investments And Advances | N/A | N/A | N/A | N/A | 0.00 | |||
| Goodwill | 22.86M | 22.86M | 22.90M | 22.90M | N/A | |||
| Intangibles | 107.05M | 109.76M | 120.60M | 131.50M | N/A | |||
| Other Non-Current Assets | 4.61M | 4.54M | 4.70M | 800.00K | 200.00K | |||
| Total Non-Current Assets | 163.34M | 166.34M | 157.70M | 161.80M | 7.00M | |||
| TOTAL ASSETS | 336.62M | 322.60M | 344.50M | 304.40M | 159.20M | |||
| LIABILITIES | ||||||||
| Current Liabilities | ||||||||
| Short Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
| Accrued Expenses | 64.17M | 63.35M | 66.40M | 68.10M | 24.80M | |||
| Accounts Payable | 7.09M | 11.56M | 4.60M | 8.90M | 3.10M | |||
| Other Current Liabilities | 1.82M | 20.28M | 2.70M | 2.00M | 300.00K | |||
| Total Current Liabilities | 73.08M | 95.19M | 73.60M | 79.00M | 28.20M | |||
| Non-Current Liabilities | ||||||||
| Long Term Debt | 229.67M | 190.93M | 187.10M | 88.10M | 87.00M | |||
| Deferred Taxes/Income | 2.58M | 2.27M | 3.50M | 4.90M | N/A | |||
| Other Non-Current Liabilities | 40.46M | 40.99M | 35.10M | 37.10M | 10.20M | |||
| Total Non-Current Liabilities | 272.71M | 234.19M | 225.70M | 130.10M | 97.20M | |||
| TOTAL LIABILITIES | 345.79M | 329.38M | 299.30M | 209.10M | 125.40M | |||
| SHAREHOLDERS' EQUITY | ||||||||
| Retained Earnings | -636.00M | -617.02M | -554.80M | -460.10M | -337.40M | |||
| Additional Paid In Capital | 626.85M | 610.25M | 600.00M | 555.40M | 371.10M | |||
| Common Shares | 15.00K | 14.00K | 0.00 | 0.00 | 0.00 | |||
| Other Shareholders' Equity | -36.00K | -25.00K | 0.00 | 0.00 | 0.00 | |||
| Shares Outstanding | 148.22M | 138.13M | 136.30M | 124.90M | 59.60M | |||
| Tangible Book Value per Share | -0.94 | -1.01 | -0.72 | -0.47 | 0.57 | |||
| Total Shareholders' Equity | -9.18M | -6.78M | 45.20M | 95.20M | 33.80M | |||
| TOTAL LIABILITIES AND EQUITY | 336.62M | 322.60M | 344.50M | 304.40M | 159.20M | |||
| Statistics | ||||||||
| Debt/Equity | -25.02 | -28.15 | 4.14 | 0.93 | 2.57 | |||
| Current Ratio | 2.37 | 1.64 | 2.54 | 1.81 | 5.40 | |||
| Return On Assets (ROA) | -19.13% | -19.30% | -27.49% | -40.31% | -57.22% | |||
| Return On Equity (ROE) | N/A | N/A | -209.51% | -128.89% | -269.53% | |||
All data in USD